BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, June 8, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 25, 2019

View Archived Issues

GABA Therapeutics and ATAI Life Sciences to develop GRX-917 for the treatment of mood disorders

Read More

Senolytics work as advertised

Read More

European Commission approves Epidyolex for the treatment of LGS and Dravet syndrome

Read More

Ovid announces positive initial data from ongoing ENDYMION extension trial of soticlestat

Read More

Phase III study of StrataGraft regenerative tissue meets both primary endpoints

Read More

PhoenixMD receives FDA clearance to initiate phase I/Ib study of PMD-026

Read More

Positive topline results presented from phase II STAR study of tolperisone

Read More

Nanobiotix presents phase I data from phase I/II study of NBTXR-3 in HCC

Read More

Phase I study of the oncolytic virus DNX-2401 in diffuse intrinsic pontine glioma

Read More

Trabectedin does not improve PFS and OS compared to standard of care in patients with meningioma

Read More

CRISPR/Cas9-mediated editing of hepatic G6pc as new model of glycogen storage disease type 1

Read More

Discovery of a novel 5-miRNA biomarker panel for early detection of NSCLC

Read More

New approach prevents GvHD, unintended consequences

Read More

Psoriasis drugs may be repurposed to treat osteosarcoma

Read More

Cytokines found to be prognostic in stage IA lung adenocarcinoma

Read More

Synthesis and evaluation of a novel radiolabeled peptide targeting GnRH receptor for prostate cancer

Read More

Novel mouse model of pancreatic cancer-induced cachexia mimicking human features

Read More

Bristol-Myers Squibb patents FPR1 and FPR2 agonists

Read More

Novartis patent details HBsAg secretion inhibitors

Read More

Inflazome reports new NLRP3 inflammasome inhibitors

Read More

Reaction Biology prepares and tests HDAC inhibitors

Read More

Pediatric phase III trial of dasiglucagon for severe hypoglycemia meets primary endpoint

Read More

Constellation begins phase I/II trial of CPI-0209 in advanced solid tumors

Read More

Incyte identifies PI3Kgamma inhibitors

Read More

FDA clears Linnaeus' IND for phase I/II trial of LNS-8801 in advanced cancer

Read More

FDA accepts Tarsius' IND for TRS-01 for ocular diseases

Read More

European Commission approves Vitrakvi for solid tumors with NTRK gene fusion

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2026.
  • New York University identifies new analogues of mannose-6-phosphate

    BioWorld Science
    New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
  • Liver disease

    FB-7033 demonstrates efficacy in MASH management

    BioWorld Science
    17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
  • Illustration of antibody carrying radioactive isotope

    Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC

    BioWorld Science
    At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...
  • Bial-Portela discovers new OX1 receptor antagonists

    BioWorld Science
    Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing